Read by QxMD icon Read

Weekly paclitaxel

Jared Weiss, Jill Gilbert, Allison Mary Deal, Mark Weissler, Chris Hilliard, Bhishamjit Chera, Barbara Murphy, Trevor Hackman, Jay Justin Liao, Juneko Grilley Olson, David Neil Hayes
BACKGROUND: Although induction studies of TPF in SCCHN have not improved outcomes compared to chemoradiotherapy alone, phase II studies of weekly carboplatin (CbP), paclitaxel and cetuximab (C225) have shown promising results. Nano-albumin-paclitaxel (nab-paclitaxel) based chemotherapy has demonstrated a higher response rate (RR) than solvent-based paclitaxel in squamous cell carcinoma of the lung with favorable toxicity. MATERIALS AND METHODS: Patients with treatment naïve SCCHN of any site with ≥N2b disease or that was unresectable by strict criteria were eligible...
September 2018: Oral Oncology
Yongfeng Tian, Hua Zhang, Yanmei Qin, Dong Li, Yang Liu, Hao Wang, Li Gan
As a major cause for the inefficiency of cancer chemotherapy, multidrug resistance (MDR) has become a major barrier to cancer treatment. Mitochondrion-orientated transportation of smart liposomes has been developed as a promising strategy to deliver anticancer drugs directly to tumor sites and actively target the mitochondria, so that drugs can interfere with mitochondrial function and facilitate cell apoptosis, overcoming MDR. Herein, we report a novel dual-functional paclitaxel (PTX) liposome system possessing both CD44 targeting and mitochondrial targeting properties to enhance drug accumulation in mitochondria and trigger apoptosis of drug-resistant cancer cells...
August 16, 2018: Drug Development and Industrial Pharmacy
Mothaffar Rimawi, Jean-Marc Ferrero, Juan de la Haba-Rodriguez, Christopher Poole, Sabino De Placido, C Kent Osborne, Roberto Hegg, Valerie Easton, Christine Wohlfarth, Grazia Arpino
Purpose To assess pertuzumab plus trastuzumab and an aromatase inhibitor (AI) in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive metastatic/locally advanced breast cancer (MBC/LABC). Patients and Methods The PERTAIN trial (NCT01491737) is an ongoing randomized, open-label, multicenter-80 sites and eight countries-phase II trial. Patients have HER2-positive, hormone receptor-positive MBC/LABC and no prior systemic therapy with the exception of endocrine. Random assignment was 1:1 to intravenous pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks) plus trastuzumab (8 mg/kg followed by 6 mg/kg every 3 weeks), and oral anastrozole (1 mg every day) or letrozole (2...
August 14, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Norbert Marschner, Christoph Salat, Ulrike Söling, Richard Hansen, Sina Grebhardt, Johanna Harde, Arnd Nusch, Karin Potthoff
BACKGROUND: One of the most effective chemotherapies for metastatic breast cancer (MBC) is nab-paclitaxel (nab-P), which is approved for treatment of MBC after failure of first-line therapy and when anthracyclines are not indicated. Randomized clinical trials have shown high efficacy and acceptable toxicity. Real-world data of nab-P in MBC, however, are still limited. PATIENTS AND METHODS: The prospective multicenter noninterventional study NABUCCO collected data on the routine treatment of patients with MBC receiving nab-P in 128 sites across Germany...
August 9, 2018: Clinical Breast Cancer
Corey J Langer, Edward S Kim, Eric C Anderson, Robert M Jotte, Manuel Modiano, Daniel E Haggstrom, Matei P Socoteanu, David A Smith, Christopher Dakhil, Kartik Konduri, Tymara Berry, Teng J Ong, Alexandra Sanford, Katayoun Amiri, Jonathan W Goldman, Jared Weiss
The phase 4 ABOUND.70+ trial assessed the safety and efficacy of nab -paclitaxel/carboplatin continuously or with a 1-week break between cycles in elderly patients with advanced non-small cell lung cancer (NSCLC). Patients ≥70 years with locally advanced/metastatic NSCLC were randomized 1:1 to first-line nab -paclitaxel days 1, 8, 15 plus carboplatin day 1 of a 21-day cycle (21d) or the same nab -paclitaxel/carboplatin regimen with a 1-week break between cycles (21d + break; 28d). The primary endpoint was the percentage of patients with grade ≥ 2 peripheral neuropathy (PN) or grade ≥ 3 myelosuppression...
2018: Frontiers in Oncology
Prasad Apsangikar, Sunil Chaudhry, Manoj Naik, Shashank Deoghare, Jamila Joseph
INTRODUCTION: The present study for biosimilar trastuzumab was a multicentric, randomized, two-arm parallel-group, comparative phase III study in patients with metastatic breast cancer. MATERIALS AND METHODS: Stage I of the study was conducted among 42 participants with equal distribution in the study and reference arm. After a loading dose of 8 mg/kg trastuzumab was administered intravenously on day 1 of the first cycle; serum samples were obtained at 0, 1.5 (end of IP infusion), 3, 6, 8, 24, 96, 168, and 336 h after the first infusion for the first cycle only...
October 2017: Indian Journal of Cancer
Takashi Kuwayama, Seigo Nakamura, Naoki Hayashi, Toshimi Takano, Koichiro Tsugawa, Takanobu Sato, Akira Kitani, Hiromi Okuyama, Hideko Yamauchi
BACKGROUND: Weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) demonstrated greater efficacy with less toxicity than docetaxel in metastatic breast cancer. We conducted a randomized phase II to compare these regimens as neoadjuvant chemotherapy for HER2- early-stage breast cancer. PATIENTS AND METHODS: Stage I-III human epidermal growth factor receptor-negative (HER2- ) breast cancer patients were included in the present trial and received either docetaxel every 3 weeks or nab-paclitaxel on days 1, 8, and 15 every 28 days for 4 cycles, followed by FEC (5-fluorouracil, epirubicin, cyclophosphamide) every 3 weeks for 4 cycles...
June 27, 2018: Clinical Breast Cancer
Diane Pannier, Antoine Adenis, Emilie Bogart, Eric Dansin, Stéphanie Clisant-Delaine, Emilie Decoupigny, Anne Lesoin, Eric Amela, Sandrine Ducornet, Jean-Pierre Meurant, Marie-Cécile Le Deley, Nicolas Penel
BACKGROUND: The primary aim of this trial was to determine the recommended phase II dose (RP2D) of weekly paclitaxel (wP) administered in combination with oral metronomic cyclophosphamide (OMC). METHODS: Patients ≥ 18 years of age with refractory metastatic cancers were eligible if no standard curative measures existed. Paclitaxel was administered IV weekly (D1, D8, D15; D1 = D28) in combination with a fixed dose of OMC (50 mg twice a day). A 3 + 3 design was used for dose escalation of wP (40 to 75 mg/m2 ) followed by an expansion cohort at RP2D...
July 31, 2018: BMC Cancer
Adrianus J de Langen, M Jebbink, Sayed M S Hashemi, Justine L Kuiper, J de Bruin-Visser, Kim Monkhorst, Erik Thunnissen, Egbert F Smit
BACKGROUND: HER2 expression and amplification are observed in ~15% of tumour biopsies from patients with a sensitising EGFR mutation who develop EGFR TKI resistance. It is unknown whether HER2 targeting in this setting can result in tumour responses. METHODS: A single arm phase II study was performed to study the safety and efficacy of trastuzumab and paclitaxel treatment in patients with a sensitising EGFR mutation who show HER2 expression in a tumour biopsy (IHC ≥ 1) after progression on EGFR TKI treatment...
July 31, 2018: British Journal of Cancer
Thomas Stahnke, Stefan Siewert, Thomas Reske, Wolfram Schmidt, Klaus-Peter Schmitz, Niels Grabow, Rudolf F Guthoff, Andreas Wree
To prevent implant failure due to fibrosis is a major objective in glaucoma research. This study investigated the antifibrotic effects of paclitaxel (PTX), caffeic acid phenethyl ester (CAPE), and pirfenidone (PFD) coated microstent test specimens in a rat model. Test specimens based on a biodegradable blend of Poly(4-hydroxybutyrate) biopolymer and atactic Poly(3-hydroxybutyrate) were manufactured, equipped with local drug delivery (LDD) coatings, and implanted in the subcutaneous white fat depot. Postoperatively, test specimens were explanted and analyzed for residual drug content...
July 30, 2018: Bioscience Reports
Ignace Vergote, Roger von Moos, Luis Manso, Els Van Nieuwenhuysen, Nicole Concin, Cristiana Sessa
BACKGROUND: Tumor Treating Fields (TTFields) are an anti-mitotic therapy comprising continuous delivery of low-intensity alternating electric fields at intermediate frequencies to the tumor region by a home-use medical device. METHODS: The INNOVATE (EF-22) Study was a phase 2, single arm clinical trial, which tested the safety and efficacy of TTFields (200 kHz) in combination with weekly paclitaxel (weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day-cycle; starting dose 80 mg/m2 ) in 31 patients with recurrent, platinum-resistant ovarian carcinoma...
July 27, 2018: Gynecologic Oncology
Razieh Avan, Ghasem Janbabaei, Narjes Hendouei, Abbas Alipour, Samaneh Borhani, Nasim Tabrizi, Ebrahim Salehifar
Background: The primary side effect of adjuvant chemotherapy with taxanes is the taxane-induced peripheral neuropathy (TIPN), which may have substantial negative impacts on patients' quality of life (QOL). We investigated the effect of pregabalin and duloxetine on QOL of breast cancer patients who experienced TIPN. Materials and Methods: This was a randomized, double-blind clinical trial conducted at a chemotherapy center of Mazandaran University of Medical Sciences, Sari, Iran...
2018: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
Satoshi Koyama, Kazunori Fujiwara, Kanae Nosaka, Takahiro Fukuhara, Tsuyoshi Morisaki, Naritomo Miyake, Hiroya Kitano, Hiromi Takeuchi
Primary squamous cell carcinoma (SCC) in the thyroid is extremely rare and has been reported in < 1% of all thyroid cancer cases. Primary SCC in the thyroid was thought to be a transitional form derived from adenocarcinomas; therefore, the majority of reported cases have focused on the conjunction with other histological adenocarcinomas. A 73-year-old male presented to our hospital with bilateral vocal fold palsy and an anterior neck mass. Ultrasound sonography revealed a bulky tumor in the thyroid and bilateral cervical lymphadenopathy...
May 2018: Case Reports in Oncology
Wen Zhang, Chunxia Du, Yongkun Sun, Lin Yang, Chengxu Cui, Zhichao Jiang, Chengfeng Wang, Jinwang Wang, Aiping Zhou
PURPOSE: We conducted a single-arm prospective phase II study to determine the efficacy and safety of the first-line treatment of advanced pancreatic cancer with nab-paclitaxel and S-1 followed by S-1 maintenance therapy. METHODS: Nab-paclitaxel was administered intravenously on days 1 and 8 at 120 mg/m2 . S-1 at 120 mg/day (for surface area ≥ 1.5 m2 ), 100 mg/day (for surface area between 1.25-1.5 m2 ), and 80 mg/day (for surface area < 1.25 m2 ) were given two times daily on days 1-14 every 3 weeks...
July 23, 2018: Cancer Chemotherapy and Pharmacology
Y-J Bang, E Yañez Ruiz, E Van Cutsem, K-W Lee, L Wyrwicz, M Schenker, M Alsina, M-H Ryu, H-C Chung, L Evesque, S-E Al-Batran, S H Park, M Lichinitser, N Boku, M H Moehler, J Hong, H Xiong, R Hallwachs, I Conti, J Taieb
Background: There currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in whom two prior lines of therapy have failed. The randomised, phase 3 JAVELIN Gastric 300 trial compared avelumab vs physician's choice of chemotherapy as third-line therapy in patients with advanced GC/GEJC. Patients and methods: Patients with unresectable, recurrent, locally advanced, or metastatic GC/GEJC were recruited at 147 sites globally...
July 24, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
B M Cook, K M Wozniak, D A Proctor, R B Bromberg, Y Wu, B S Slusher, B A Littlefield, M A Jordan, L Wilson, Stuart C Feinstein
The reversibility of chemotherapy-induced peripheral neuropathy (CIPN), a disabling and potentially permanent side effect of microtubule-targeting agents (MTAs), is becoming an increasingly important issue as treatment outcomes improve. The molecular mechanisms regulating the variability in time to onset, severity, and time to recovery from CIPN between the common MTAs paclitaxel and eribulin are unknown. Previously (Benbow et al. in Neurotox Res 29:299-313, 2016), we found that after 2 weeks of a maximum tolerated dose (MTD) in mice, paclitaxel treatment resulted in severe reductions in axon area density, higher frequency of myelin abnormalities, and increased numbers of Schwann cell nuclei in sciatic nerves...
July 26, 2018: Neurotoxicity Research
Kayo Kayahashi, Yasunari Mizumoto, Subaru Myojo, Yusuke Mitani, Atsushi Tajima, Hiroshi Fujiwara
Recent reports showed that neoadjuvant chemotherapy (NAC) has been successfully applied to treat advanced uterine cervical cancers during pregnancy. However, its side effects on the fetus remain unclear. Here, we report a 33-year-old primipara who underwent four courses of NAC therapy, paclitaxel and cisplatin, from 17 to 27 weeks of gestation due to uterine cervical cancer stage IB2. At 31 weeks of gestation, cesarean section and radical hysterectomy were performed, and a female baby weighing 1446 g was born...
July 25, 2018: Journal of Obstetrics and Gynaecology Research
Tadashi Higuchi, Yoichi Nakamura, Hodaka Moriyama, Ryohei Watanabe, Asako Takahashi, Sayaka Nagao, Toshiyuki Enomoto, Manabu Watanabe, Yoshihisa Saida, Shinya Kusachi
Orbital metastasis of gastric cancer occurs very rarely.A 76-year-old woman, who consulted another doctor with the chief complaints of palpitation, shortness of breath, and anorexia 1 month previously, was referred to our clinic for workup and treatment.Workup revealed type III advanced gastric cancer at the lesser curvature of the gastric antrum.Biopsy revealed a diagnosis of poorly differentiated adenocarcinoma.As computed tomography suggested periaortic lymph node metastasis, a diagnosis of T4a(SE)N3aM1(LYM), cStage IV was made...
July 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Akari Murakami, Yoshiaki Kamei, Erina Kusakabe, Haruna Yamasawa, Reina Aoki, Saaya Komatsu, Kana Taguchi, Kanako Nishiyama, Michiko Yamashita, Wakana Sugimori, Hiroaki Asai, Yosuke Mizuno, Yasutsugu Takada
We report a case of microangiopathic hemolytic anemia(MHA)caused by metastatic breast cancer treated with weekly paclitaxel. A 58-year-old woman was diagnosed with metastatic breast cancer 2 years earlier. She was treated with various chemotherapy regimens and hormonal therapy, before being switched to fulvestrant 3 months earlier. She presented with severe anemia, and was diagnosed with MHA with bone marrow carcinomatosis following bone marrow biopsy. She was treated with weekly paclitaxel and recovered successfully...
July 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Nami Ishikawa, Michiyo Saimura, Kenichiro Koga, Keisei Anan, Shoshu Mitsuyama, Sadafumi Tamiya
Metaplastic carcinoma is a rare type of breast carcinoma, which tends to be chemo-resistant. We report a case of metaplastic squamous cell carcinoma of the breast diagnosed after neoadjuvant chemotherapy(NAC). A 56-year-old woman was diagnosed as having right-sided breast cancer(invasive ductal carcinoma[IDC], triple negative), cT1cN1M0, stage II A. NAC with 5-fluorouracil, epirubicin, and cyclophosphamide(FEC)followed by docetaxel(DTX)was administered. Tumor progression occurred during both the FEC and DTX regimens...
July 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"